Vupanorsen clinical trials
Also written AKCEA-ANGPTL3-LRx and ISIS 703802.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How each study uses vupanorsen is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2017 | 2 |
| 2018 | 2 |
| 2020 | 2 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Studies
Open first, then newest update. How each study uses vupanorsen is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Tolerability Of Single Dose Vupanorsen In Healthy Chinese AdultsCompletedPhase 1PfizerNCT04916795Written as Vupanorsen
- A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)CompletedPhase 2PfizerNCT04516291Written as Vupanorsen
- Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL)CompletedPhase 2Akcea TherapeuticsNCT03514420Written as AKCEA-ANGPTL3-LRx
- Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver DiseaseCompletedPhase 2Akcea TherapeuticsNCT03371355Written as ISIS 703802 40 mg
- Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS)CompletedPhase 2Akcea TherapeuticsNCT03360747Written as AKCEA-ANGPTL3-LRx
- Investigation Of Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Doses Of Vupanorsen In Japanese Healthy Adult Participants With Elevated TriglyceridesCompletedPhase 1PfizerNCT04459767Written as Vupanorsen
- Study of AKCEA-ANGPTL3-LRX (ISIS 703802) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)WithdrawnPhase 2Akcea TherapeuticsNCT03455777Written as AKCEA-ANGPTL3-LRX
Codes
What other systems call vupanorsen · ClinicalTrials.gg INT001942
- UNII (FDA) A7YG62NHZ6VUPANORSENOne source FDA
- NCI Thesaurus C174612VupanorsenOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | A7YG62NHZ6 | VUPANORSEN | One source FDA |
| NCI Thesaurus | C174612 | Vupanorsen | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.